Merck Entered into a WW Research Collaboration and License Agreement with Synthekine to Develop Novel Cytokine Therapeutics
Shots:
- Synthekine to receive up front along with an additional one-time payment, if selects a second target & will be eligible for ~$525M in development, regulatory, and commercialization milestones along with royalties on net sales for each target
- Merck to get exclusive rights to develop, manufacture, and commercialize surrogate cytokine agonists for up to two cytokine targets. Synthekine is responsible for initial research efforts in collaboration with Merck
- The collaboration will utilize Synthekines surrogate cytokine agonist platform to discover, develop, and commercialize novel cytokine therapeutics for the treatment of autoimmune diseases
Ref: Synthekine | Image: Merck
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com